⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361240 | 0.69 | — | — | |
| SCHEMBL27594831 | 0.69 | — | — | |
| SCHEMBL28858024 | 0.69 | — | — | |
| SCHEMBL1479288 | 0.67 | — | — | |
| SCHEMBL5909 | 0.67 | — | — | |
| SCHEMBL922360 | 0.64 | — | — | |
| SCHEMBL27412887 | 0.62 | — | — | |
| SCHEMBL9949606 | 0.62 | — | — | |
| SCHEMBL570228 | 0.62 | — | — | |
| Acetic Acid SCHEMBL19331447 | 0.60 | FFAR3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113057959-B | Ketohexokinase (KHK) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-112243461-B | Molecular barcoding at opposite transcript ends | 贝克顿迪金森公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-112313335-B | Renin (AGT) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118265791-A | Spherical nucleic acids for cGAS-STING and STAT3 pathway modulation for immunotherapeutic treatment of cancer | 西北大学 | 2024-06-28 | — | — | CN | disclosed |
| CN-118119709-A | NR4A3 defective cells and uses thereof | 莱尔免疫制药公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118079015-A | Methods and compositions for treating proprotein convertase subtilisin KEXIN (PCSK 9) gene-related disorders | 阿尔尼拉姆医药品有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118076735-A | NR4A3 defective immune cells and uses thereof | 莱尔免疫制药公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117835986-A | Microglial gene silencing using double stranded siRNA | 阿塔兰塔治疗公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117795069-A | Compositions and methods for delivering therapeutic oligonucleotides to the central nervous system | 阿塔兰塔治疗公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117716040-A | Compositions and methods for inhibiting nerve growth factor and treating/preventing atrial fibrillation | 西北大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-116732004-A | CRISPR-Cas effector polypeptides and methods of use thereof | 加利福尼亚大学董事会 | 2023-09-12 | — | — | CN | disclosed |
| CN-109906274-B | Methods for cell marker classification | 贝克顿迪金森公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116635061-A | Immunooncology therapies with IL-2 conjugates | 新索思股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116615247-A | Combination therapy of immunooncology with IL-2 conjugates and pembrolizumab | 新索思股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116262917-A | G-quadruplex-containing nucleic acids | 成都凌泰氪生物技术有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116262919-A | Nucleic acid molecule based on miRNA-2911 | 成都凌泰氪生物技术有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116209465-A | Immunooncology combination therapy with IL-2 conjugates and anti-EGFR antibodies | 新索思股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116157520-A | Compositions and methods for genome editing | 塑造治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116096739-A | Chimeric antigen receptor spacers | 莱尔免疫制药公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-105037278-B | Sirt5 regulator and its screening technique | 康奈尔大学 | 2019-05-03 | — | — | CN | disclosed |